Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Gene | IDH2 |
| Variant | R140Q |
| Impact List | missense |
| Protein Effect | gain of function |
| Gene Variant Descriptions | IDH2 R140Q lies within the substrate binding region of the Idh2 protein (UniProt.org). R140Q confers a gain of function to Idh2, enabling conversion of alpha-ketoglutarate to the onco-metabolite 2HG (R(-)-2-hydroxyglutarate), results in increased 2HG levels in patient samples, and is transforming in cell culture (PMID: 20171147, PMID: 23558173). |
| Associated Drug Resistance | |
| Category Variants Paths |
IDH2 mutant IDH2 act mut IDH2 R140Q IDH2 mutant IDH2 R140X IDH2 R140Q |
| Transcript | NM_002168.4 |
| gDNA | chr15:g.90088702C>T |
| cDNA | c.419G>A |
| Protein | p.R140Q |
| Source Database | RefSeq |
| Genome Build | GRCh38/hg38 |
| Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
|---|---|---|---|---|---|
| NM_002168.4 | chr15:g.90088702C>T | c.419G>A | p.R140Q | RefSeq | GRCh38/hg38 |
| NM_002168.3 | chr15:g.90088702C>T | c.419G>A | p.R140Q | RefSeq | GRCh38/hg38 |
| NM_002168 | chr15:g.90088702C>T | c.419G>A | p.R140Q | RefSeq | GRCh38/hg38 |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT03953898 | Phase II | Olaparib | Using the Anticancer Drug Olaparib to Treat Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome With an Isocitrate Dehydrogenase (IDH) Mutation | Active, not recruiting | USA | 0 |